Search

Your search keyword '"Mulder, PGH (Paul)"' showing total 136 results
Start Over Author "Mulder, PGH (Paul)"
136 results on '"Mulder, PGH (Paul)"'

4. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design

Author

van der Loos, MLM, Mulder, PGH (Paul), Hartong, EGTM, Blom, MBJ, Vergouwen, AC, van Noorden, MS, Timmermans, MA, Vieta, E, Nolen, WA, and Epidemiology

Abstract

Objective: In two previous manuscripts, we described the efficacy of lamotrigine versus placebo as add-on to lithium (followed by the addition of paroxetine in nonresponders) in the short-term treatment of bipolar depression. In this paper we describe the long-term (68 weeks) outcome of that study. Methods: A total of 124 bipolar depressed patients receiving lithium were randomized to addition of lamotrigine or placebo. After eight weeks, paroxetine was added to nonresponders for another eight weeks. Responders continued medication and were followed for up to 68 weeks or until a relapse or recurrence of a depressive or manic episode. Results: After eight weeks, the addition of lamotrigine to lithium was significantly more efficacious than addition of placebo, while after addition of paroxetine in nonresponders both groups further improved with no significant difference between groups at week 16. During follow-up the efficacy of lamotrigine was maintained: time to relapse or recurrence was longer for the lamotrigine group [median time 10.0 months (confidence interval: 1.1-18.8)] versus the placebo group [3.5 months (confidence interval: 0.7-7.0)]. Conclusion: In patients with bipolar depression, despite continued use of lithium, addition of lamotrigine revealed a continued benefit compared to placebo throughout the entire study.

Published
2011

5. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels

Author

Bannink, EMN (Ellen), van Sassen, C, van Buuren, S, Jong, Frank, Lequin, MH, Mulder, PGH (Paul), Schrama, Sabine, Pediatrics, Internal Medicine, Radiology & Nuclear Medicine, and Epidemiology

Abstract

Besides short stature, gonadal dysgenesis leading to a lack of oestrogen is one of the main characteristics of Turner syndrome (TS). In most TS girls, puberty is induced with exogenous oestrogens. To describe the pubertal development and uterine dimensions achieved by low-dose 17 beta-oestradiol (17 beta-E2) orally started at an appropriate age. Additionally, to determine whether serum hormone levels aid evaluation of pubertal progression. In 56 TS girls, we prospectively studied pubertal stage, serum E2, LH, FSH, SHBG and oestrone (E1), starting oestrogen treatment with a low-dose 17 beta-E2 (5 mu g/kg/day) during GH treatment at mean (SD) age 12.7 (0.7) years. Hormone levels were measured at start, 3 months after start and after increasing 17 beta-E2 dosage. Uterine dimensions were measured in 39 TS women at age 19.9 (2.2) years. Although breast and pubic hair development were similar to that in normal Dutch girls up to Tanner stage B5 and P5, respectively, breast development was 2 years later. Before oestrogen therapy, E2 levels were comparable to those in prepubertal girls. With a 17 beta-E2 dose of 5 mu g/kg/day, these levels increased significantly, becoming comparable to normal late pubertal or adult concentrations, whereas SHBG levels were unchanged. At the adult 17 beta-E2 dose, SHBG had increased significantly. Uterus shape was juvenile in four (10.2%), cylindrical in four and mature-adult shaped in 31 (79.5%) of TS patients. During GH treatment in TS girls, normal breast development up to B5 can be mimicked, with just a 2-year delay. In a clinical setting, serum hormone levels provide no additional information for evaluating pubertal progression. After age-appropriate pubertal induction, uterine dimensions in women aged nearly 20 years were subnormal. It remains unclear whether this was related to E2 dosage, timing or duration, or factors related to TS.

Published
2009

10. Repeated ankle sprains and delayed neuromuscular response: Acceleration time parameters

Author

van Cingel, REH, Kleinrensink, Gert-jan, Uitterlinden, EJ, Rooijens, P, Mulder, PGH (Paul), Aufdenkampe, G, Stoeckart, Rob, Neurosciences, Orthopedics and Sports Medicine, and Epidemiology

Subjects
GeneralLiterature_INTRODUCTORYANDSURVEY, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

No summary available

Published
2006

16. Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo-controlled multicenter trial

Author

van Rooij, FJA, Rijneveld, WJ, Remeijer, L (Lies), Völker-Dieben, HJM, Eggink, CA, Geerards, AJ, Mulder, PGH (Paul), Doornenbal, P, Beekhuis, WH (Houdijn), Epidemiology, Virology, and Ophthalmology

Subjects
genetic structures, Neurosensory disorders [UMCN 3.3]
Abstract

Item does not contain fulltext OBJECTIVE: To determine the prophylactic effect of oral acyclovir on the recurrence rate of herpetic eye disease after penetrating keratoplasty. DESIGN: A randomized, double-masked, placebo-controlled multicenter trial. PARTICIPANTS: Sixty-eight consecutive patients (68 eyes) with corneal opacities due to herpetic eye disease who underwent penetrating keratoplasty. INTERVENTION: Oral acyclovir 400 mg twice daily or placebo tablets for 6 months. MAIN OUTCOME MEASURES: The recurrence rate of herpetic eye disease-related events and rejection episodes, proven by viral cell culture or polymerase chain reaction. RESULTS: During the 2-year follow-up period, there were 3 culture-proven herpetic eye disease recurrences in the acyclovir group and 9 in the placebo group. Lifetime survival analysis of the probability of remaining free from recurrence revealed a significantly reduced risk of recurrent herpetic disease in the acyclovir-treated group. CONCLUSION: This study suggests that oral acyclovir effectively prevents herpes-related recurrences after penetrating keratoplasty in herpetic eye disease.

Published
2003

42. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multicenter study

Author

Riemsdijk-van Overbeeke, IC, Mulder, PGH (Paul), de Fijter, JW, Bruijn, Jan, van Hooff, JP, Hoitsma, A, Tegzess, AM, Weimar, Willem, Interne Geneeskunde, RS: NUTRIM School of Nutrition and Translational Research in Metabolism, Epidemiology, Psychiatry, and Internal Medicine

Subjects
RECIPIENTS, HEMODYNAMICS, LONG-TERM, Randomized studies to improve graft survival after renal transplantation, CHRONIC NEPHROPATHY, Gerandomiseerde studies ter verbetering van transplantaatoverleving na niertransplantatie, CALCIUM-CHANNEL BLOCKERS, CYCLOSPORINE PHARMACOKINETICS
Abstract

Background. After successful kidney transplantation patients may suffer from the adverse effects due to the use of calcineurin inhibitors. Calcium channel blockers are effective in the treatment of hypertension and may ameliorate cyclosporine- (CsA) induced impairment of renal function after kidney transplantation. Calcium channel blockers may also modulate the immune-system which may result in reduction of acute rejection episodes. Patients and methods. From June 1995 till 1997 the effect of isradipine (Lomir) on renal function, incidence and severity of delayed graft function (DGF), and acute rejection after kidney transplantation, was studied in 210 renal transplant recipients, who were randomized to receive isradipine (n=98) or placebo (n=112) after renal transplantation in a double-blind fashion. Results. In the isradipine group renal function was significantly better at 3 and 12 months (P=0.002 and P=0.021) compared with the placebo group. DGF was present, in both groups: isradipine: (28+6)/98 (35%); placebo: (35+9)/112 (40%), P=0.57. Severity of DGF was comparable in both groups (isradipine: 9.1+/-8.7 vs. placebo: 9.3+/-8.1 days). No statistical difference was found in incidence or severity of biopsy-proven acute rejection [isradipine: (42+6)/98 (49%) versus placebo: (46+9)/112 (49%), P=1.00]. Renal vein thrombosis was observed in eight patients, This proved to be associated with the route of administration of the study medication [6/45 (13%) on i.v. medication versus 2/165 (1%) on oral medication, P

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results